Bernstein Harold sold $437K of MAZE
Bernstein Harold (President, R&D & CMO) sold 14,609 shares of Maze Therapeutics, Inc. (MAZE) at an average of $29.90 ($29.86–$30.34, $0.44M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market sale amount and that it was executed under a pre-arranged Rule 10b5-1 plan.
Market read
Traders may monitor insider activity, but this specific disclosure lacks any fundamental catalyst in the provided text.
What to watch
The article provides only the sale details; it does not include any concurrent buys, guidance changes, or clinical/financial updates that would re-rate the stock.
Background
The article is an SEC Form 4 insider transaction disclosure for Maze Therapeutics, Inc.
Ticker impact
Form 4 shows MAZE President, R&D & CMO Harold Bernstein sold 14,609 shares in open-market trades under a 10b5-1 plan.
Limited near-term impact; any effect is likely short-lived unless accompanied by other disclosures.
The filing is a disclosed insider sale with a pre-arranged 10b5-1 plan and no accompanying operational or financial catalyst in the text.
Market effects
No sector-wide implications stated; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Insider sales under a 10b5-1 plan can reflect liquidity planning rather than bearish expectations, so price impact may be overstated.
Key entities
- issuerMaze Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderHarold Bernstein
President, R&D & CMO who sold shares under a 10b5-1 plan.